RESMED INC Q1 FY2027 earnings call

• Product Innovation & Digital Health:
  • Launched Aircurve 11 ST/STA bi-level platforms in the US for complex breathing disorders.
  • Introduced AirTouch F40 fabric mask; early data shows 6% higher adherence compared to silicone equivalents.
  • MyAir app refreshed with GenAI-powered 'Dawn' coach (2.1M+ inquiries); improves compliance from 70% to 87% when paired with AirView.
  • Smart Comfort AI feature launched, showing a 4.3% increase in 30-day compliance.
• Operational Excellence & Supply Chain:
  • Gross margin expanded 50 bps YoY, beating expectations due to favorable phasing of supply chain investments (Indiana facility build-out costs deferred to Q2).
  • First 'Made in America' CPAP (Essence 11) produced in Atlanta; Indianapolis distribution center under construction to improve North American delivery speeds.
  • Global manufacturing footprint expanded in Singapore and Malaysia to ensure resilience.
• Strategic Partnerships & Market Expansion:
  • Collaborations with Eight Sleep and Aura smart rings to drive patient awareness and diagnosis pathways.
  • GLP-1 drug analysis (3.3M+ patients) confirms users are 11% more likely to start CPAP and have higher resupply rates.
  • Marketing campaigns ('CPAP Baddies', NASCAR partnerships) aim to normalize therapy and improve adherence.
• Portfolio Management:
  • Completed divestiture of MatrixCare, focusing on core RCS growth.
  • Rapidly expanding commercial footprint for NIDRA (Restless Legs Syndrome therapy).
  • Executing comprehensive field safety corrective action for Astral devices; no longer selling Astral, prioritizing service for existing patients.

• Sleep Devices: Revenue increased by 6% in the Americas and 13% Rest of World (RoW). RoW growth was significantly aided by a fleet renewal program in France shifting from AirSense 10 to AirSense 11. Life support device revenue declined sharply (-94% in Americas, -79% RoW) due to the discontinuation of sales for the Astral device.
• Masks and Other: Revenue grew by 10% in the Americas and 11% RoW, driven by strong demand for new fabric masks like the AirTouch F40.
• Residential Care Software (RCS): Reported revenue declined 7%, but constant currency growth was 5%. Excluding the divested MatrixCare business, core RCS businesses (Bright Tree and Medifox Dan) grew by 8%.
• Overall Revenue Contribution: Total Q1 revenue was $1.4 billion. While specific percentage contributions per segment are not explicitly detailed in the text, Sleep Devices and Masks represent the primary growth drivers, while Life Support is currently a drag due to the Astral recall/discontinuation.

• Full-Year FY2027 Revenue: Reiterated guidance of 5% to 7% core constant currency growth (reported range: $5.75B - $5.85B).
  • Note: This includes an ~130 bps ($75M) headwind from stopping Astral sales. Excluding Astral, core growth would be 6.3% to 8.3%.
• Full-Year FY2027 EPS: Reiterated non-GAAP EPS guidance of $12.00 to $12.25 (approx. 7-10% reported growth).
  • Core constant currency EPS growth implied at 12% to 14% excluding M&A impacts.
• Gross Margin: Expect low double-digit basis point expansion for the full year, despite inflationary pressures on electronic components.
• Capital Returns: Targeting >$1.85 billion total return to shareholders via dividends and buybacks for FY2027.
• CapEx: Maintaining guidance of $160 million to $180 million.
• Q2 Outlook: Expect mid-single-digit sequential revenue growth; gross margin expected to decline slightly sequentially due to deferred Indiana facility costs hitting P&L; R&D flat, SG&A up due to marketing.

• Inflationary Pressures: Continued impact of inflation on electronic component costs and customer purchasing power, which may build throughout the fiscal year.
• Astral Recall Execution: Significant operational risk associated with the field safety corrective action for Astral devices; requires careful management of parts allocation and patient care.
• External Macro Environment: Uncertainty regarding global economic conditions, FX headwinds (assumed 60 bps headwind in guidance), and potential regulatory changes affecting reimbursement or market access.
• Competitive Landscape: Increasing competition in the US market, including potential re-entry of Philips and presence of React Health, though ResMed cites its ecosystem as a defensive moat.

Q: Chris Cooper (JPMorgan) asked about the drivers of the 50 bps gross margin beat and whether price increases contributed.

A: CFO Aaron Wong clarified that pricing had minimal contribution in Q1. The beat was primarily driven by productivity gains in the supply chain and favorable phasing of capital expenditures for the Indiana facility, which delayed costs into Q2. Price increases are expected to benefit margins gradually starting in H2.

Q: David Lowe (UBS) requested details on Rest of World performance, specifically France.

A: CEO Mick Farrell explained that RoW sleep device growth (+13%) was boosted by a differentiated reimbursement model in France requiring fleet renewals every five years. Customers are upgrading from AirSense 10 to cloud-connected AirSense 11 devices to maintain reimbursement eligibility, creating a temporary tailwind.

Q: Craig Wong-Pan (RBC) asked if recent marketing and partnership initiatives (Aura, Eight Sleep) impacted Q1 top-line growth.

A: Mick Farrell stated there was no material contribution to Q1 revenue yet. These initiatives are focused on long-term, durable growth by educating clinicians and driving middle-of-funnel conversions. He expects meaningful contributions later in the fiscal year, aiming for the high end of the 5-7% growth guide if executed well.

Q: Brett Fishman (KeyBanc) questioned why full-year guidance was maintained despite a strong Q1 beat.

A: Aaron Wong emphasized that guiding to the midpoint (5-7%) is prudent given only one quarter has passed. Risks include the conclusion of the France fleet tailwind in H2, ongoing inflation, and the time lag for marketing ROI. Share buyback timing also skewed EPS higher in Q1, so maintaining guidance reflects caution.

Q: Anthony Patron (Mizuho) asked how ResMed defends market share against competitors like React Health and potential Philips return.

A: Mick Farrell argued that ResMed’s competitive advantage lies in its integrated digital health ecosystem (MyAir, AirView, EHR integration) rather than just hardware. This ecosystem drives adherence (up to 87%) and lowers costs for providers/HMEs, making it difficult for competitors to displace ResMed even if they offer similar devices.